This data indicates that SC administration, with its lower incidence of systemic adverse effects and greater patient convenience, may be a preferable option for many patients undergoing treatment for HER2-positive breast cancer (Pivot et al., 2014; O’Shaughnessy et al., 2021). This evidence concerns the gene ERBB2 and breast carcinoma.